DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity

Changzheng Lu,Junhong Guan,Steve Lu,Qihuang Jin,Benoit Rousseau,Tianshi Lu,Dennis Stephens,Hongyi Zhang,Jiankun Zhu,Mingming Yang,Zhenhua Ren,Yong Liang,Zhida Liu,Chuanhui Han,Longchao Liu,Xuezhi Cao,Anli Zhang,Jian Qiao,Kimberly Batten,Mingyi Chen,Diego H Castrillon,Tao Wang,Bo Li,Luis A Diaz,Guo-Min Li,Yang-Xin Fu,Diego H. Castrillon,Luis A. Diaz
DOI: https://doi.org/10.1016/j.ccell.2020.11.006
IF: 50.3
2021-01-01
Cancer Cell
Abstract:Increased neoantigens in hypermutated cancers with DNA mismatch repair deficiency (dMMR) are proposed as the major contributor to the high objective response rate in anti-PD-1 therapy. However, the mechanism of drug resistance is not fully understood. Using tumor models defective in the MMR gene <em>Mlh1</em> (dMLH1), we show that dMLH1 tumor cells accumulate cytosolic DNA and produce IFN-β in a cGAS-STING-dependent manner, which renders dMLH1 tumors slowly progressive and highly sensitive to checkpoint blockade. In neoantigen-fixed models, dMLH1 tumors potently induce T cell priming and lose resistance to checkpoint therapy independent of tumor mutational burden. Accordingly, loss of STING or cGAS in tumor cells decreases tumor infiltration of T cells and endows resistance to checkpoint blockade. Clinically, downregulation of cGAS/STING in human dMMR cancers correlates with poor prognosis. We conclude that DNA sensing within tumor cells is essential for dMMR-triggered anti-tumor immunity. This study provides new mechanisms and biomarkers for anti-dMMR-cancer immunotherapy.
oncology,cell biology
What problem does this paper attempt to address?
The problem this paper attempts to address is the exploration of the DNA sensing mechanism in mismatch repair-deficient (dMMR) tumor cells and its role in anti-tumor immunity, as well as further revealing how this mechanism affects the efficacy of immune checkpoint blockade (ICB) therapy. Specifically, the study found that dMMR tumor cells accumulate cytosolic DNA and activate the cGAS-STING pathway, thereby producing interferon-β (IFN-β) and enhancing the anti-tumor immune response. However, when cGAS or STING is knocked out in dMMR tumor cells, the tumors develop resistance to immune checkpoint blockade therapy. Additionally, the study also indicates that in human dMMR cancers, downregulation of the cGAS-STING pathway expression is associated with drug resistance. Overall, this paper reveals that the DNA sensing mechanism within dMMR tumor cells is crucial for triggering anti-tumor immunity and provides new mechanisms and biomarkers to guide the immunotherapy of dMMR cancers.